Drug Profile


Alternative Names: Lorexys; Orexa; S1P-104; S1P-205; SIP-104; Trazodone/bupropion

Latest Information Update: 12 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator S1 Pharmaceuticals
  • Developer S1 Biopharma
  • Class Erectile dysfunction therapies; Piperazines; Propiophenones; Pyridones; Small molecules
  • Mechanism of Action Adrenergic uptake inhibitors; Alpha adrenergic receptor agonists; Dopamine uptake inhibitors; Serotonin 2A receptor antagonists; Serotonin 2C receptor antagonists; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Sexual function disorders

Highest Development Phases

  • Phase II Female sexual dysfunction
  • Preclinical Male sexual dysfunction

Most Recent Events

  • 12 Sep 2016 Preclinical development is ongoing in USA (S1 Biopharma pipeline, September 2016)
  • 12 Sep 2016 Phase-II clinical trials in Female sexual dysfunction in USA (PO) before September 2016 (S1 Biopharma pipeline)
  • 08 Dec 2015 Bupropion/trazodone licensed to CKD Pharmaceuticals in South Korea for commercialisation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top